Cell encapsulation

Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for Endocrine Disorders

Retrieved on: 
Wednesday, December 13, 2023

Encellin , a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.

Key Points: 
  • Encellin , a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.
  • Preclinical data with its first candidate, using ENC-201 in T1D, reported no fibrosis, or immune response, while maintaining cell viability and function.
  • “This new financing led by Khosla Ventures, enables us to advance development of our Cell Encapsulation platform, which aims to provide years of therapeutic benefit with a single implant.
  • The technology can be used in a variety of different indications, beginning with chronic endocrine disorders,” said Crystal Nyitray, Ph.D., CEO & Co-Founder, Encellin.

Live Cell Encapsulation - The Bioengineering Breakthrough Revolutionizing Therapeutics with Controlled Drug Delivery - ResearchAndMarkets.com

Retrieved on: 
Monday, August 7, 2023

Live cell encapsulation, a cutting-edge bioengineering technology, entails encasing living cells with specialized materials or coatings.

Key Points: 
  • Live cell encapsulation, a cutting-edge bioengineering technology, entails encasing living cells with specialized materials or coatings.
  • Live cell encapsulation holds immense promise in the treatment of chronic diseases, including type 1 diabetes, cancer, and autoimmune disorders.
  • Notable partnerships and collaborations, like BIO INX and Nanoscribe's HYDROBIO INX N400, offering 3D printing-enabled cell encapsulation, underscore the potential of live cell encapsulation.
  • Detailed analysis of the major companies present in the Global Live Cell Encapsulation Market include:

Sphere Fluidics Updates Brand Identity to Align With Ambitious, Global Commercial Growth Strategy

Retrieved on: 
Tuesday, May 23, 2023

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the introduction of new branding to align with its ambitious global commercial growth strategy.

Key Points: 
  • Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, today announced the introduction of new branding to align with its ambitious global commercial growth strategy.
  • The update has been introduced to better reflect the Company’s customer-centric approach and showcase its pioneering single cell discovery and analysis technology, following a period of significant growth and program success.
  • Sphere Fluidics’ range of novel cell encapsulation products for single cell analysis and isolation are aimed at easing customer workflows to accelerate scientific discovery.
  • Sphere Fluidics’ core focus is on working with scientists to solve throughput challenges.

Microencapsulation Market Report 2023: Featuring Capsulae, LycoRed, BASF, Reed Pacific, Bayer, Evonik & More - ResearchAndMarkets.com

Retrieved on: 
Friday, March 10, 2023

The global microencapsulation market size is anticipated to reach USD 25,974.0 million by 2030, registering a CAGR of 10.3% from 2023 to 2030.

Key Points: 
  • The global microencapsulation market size is anticipated to reach USD 25,974.0 million by 2030, registering a CAGR of 10.3% from 2023 to 2030.
  • Furthermore, the introduction of new fibers by the global players in the market is expected to raise the demand for microencapsulation during the forecast period.
  • For instance, a composite fiber called Crabyon from chitosan that Pozzi Electra had created is well-known for its therapeutic capabilities.
  • In addition, Solvay launched Emana a polyamide 6.6 yarn containing bioactive mineral crystals in its polymer matrix.

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Retrieved on: 
Wednesday, February 2, 2022

This immune-evasive cell replacement therapy is designed to enable patients to produce their own insulin.

Key Points: 
  • This immune-evasive cell replacement therapy is designed to enable patients to produce their own insulin.
  • If this approach is successful, it will be a transformative treatment for patients with all insulin-requiring forms of diabetes.
  • The Phase 1 clinical trial of VCTX210 will assess its safety, tolerability, and immune evasion in patients with T1D.
  • CRISPR THERAPEUTICS word mark and design logo, are registered trademarks of CRISPR Therapeutics AG.

ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of Directors

Retrieved on: 
Wednesday, January 19, 2022

"We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.

Key Points: 
  • "We are excited to welcome Alyssa and Lisa to ViaCyte to ensure we are well-positioned for the future as we continue advancing ground-breaking therapeutics for type 1 diabetes," said Michael Yang, President and Chief Executive Officer, ViaCyte.
  • "I am excited to lead the finance team as we pursue significant clinical and growth opportunities to create increased value across our pipeline."
  • Previously, Ms. Levin was Chief Financial Officer at Bird Rock Bio, a clinical-stage bio-pharmaceutical company focused on the treatment of fibrotic, metabolic and inflammatory diseases.
  • Prior to Nano Precision Medical, Dr. Porter was Chief Medical Officer for Eiger Biopharmaceuticals, Inc. and Dance Biopharma, Inc. (now Aerami Therapeutics).

ViaCyte Appoints Marty Lorenzo as General Counsel

Retrieved on: 
Tuesday, November 30, 2021

SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- ViaCyte, Inc. , a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced the appointment of Marty Lorenzo as General Counsel.

Key Points: 
  • SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- ViaCyte, Inc. , a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced the appointment of Marty Lorenzo as General Counsel.
  • Mr. Lorenzo brings over 20 years in the legal profession leading corporate transactions and compliance functions.
  • "We are excited to have Marty join the ViaCyte management team," said Michael Yang, President and Chief Executive Officer of ViaCyte.
  • "I am thrilled to be part of ViaCyte as the Company advances transformational cell therapies to the clinic with the potential to deliver functional cures," said Mr. Lorenzo.

CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

Retrieved on: 
Tuesday, November 16, 2021

ZUG, Switzerland and CAMBRIDGE, Mass. and SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today announced that Health Canada has approved the companies’ Clinical Trial Application (CTA) for VCTX210, an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D). Initiation of patient enrollment is expected by year-end.

Key Points: 
  • The combination of ViaCytes leading stem cell capabilities and CRISPR Therapeutics pre-eminent gene-editing platform has the potential to meaningfully impact the lives of patients living with type 1 diabetes.
  • The Phase 1 clinical trial of VCTX210 is designed to assess its safety, tolerability, and immune evasion in patients with T1D.
  • This program is being advanced by CRISPR Therapeutics and ViaCyte as part of a strategic collaboration for the discovery, development, and commercialization of gene-edited stem cell therapies for the treatment of diabetes.
  • CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

ViaCyte to Present at the Jefferies Gene Therapy/Editing Summit

Retrieved on: 
Wednesday, October 20, 2021

SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that Michael Yang, President & CEO, will present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 11:30 a.m.

Key Points: 
  • SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that Michael Yang, President & CEO, will present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 11:30 a.m.
  • A live webcast of this presentation will be available on the Company's News & Events page accessible here: https://viacyte.com/news-events/ .
  • To accelerate and expand the Company's efforts, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L.
  • For more information, please visit www.viacyte.com and connect with ViaCyte on Twitter , Facebook , and LinkedIn .

ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa

Retrieved on: 
Thursday, October 7, 2021

SAN DIEGO, Oct. 7, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that it will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14, 2021, at 10:15 a.m. PT in Carlsbad, CA.

Key Points: 
  • SAN DIEGO, Oct. 7, 2021 /PRNewswire/ -- ViaCyte, Inc. , an innovator in cellular therapy and regenerative medicine, announced today that it will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa on October 14, 2021, at 10:15 a.m. PT in Carlsbad, CA.
  • "Cell replacement therapy has the potential to address the limitations of current therapies and advance the treatment of diabetes," said Mr. Yang.
  • ViaCyte is a privately held clinical-stage regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation.
  • To accelerate and expand the Company's efforts, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L.